Abstracts
PHP21 SOURCES OF MEDICATION FOR PATIENTS IN GENERAL MEDICINE
Tungol A, Erickson S, Kucukarslan S University of Michigan College of Pharmacy, Ann Arbor, MI, USA OBJECTIVES: To examine the influence of inexpensive generic programs on prescription medication acquisition behavior of patients. METHODS: Cross-sectional survey of 200 consecutive patients during regularly scheduled appointments to an adult general medicine clinic. Questions were asked to determine the type of pharmacy patients obtained their current prescription medication from; whether they were aware of focused programs selling generic medication for a reduced cost; whether they had filled a prescription recently using a reduced cost generic program, and if they did, whether they had other medications filled at the same pharmacy. Demographic data was also obtained. Data were analyzed using descriptive statistics. Respondents were categorized as having filled a prescription using an inexpensive generic program or not. Differences in demographics and medication-related variables between the two groups were analyzed using Student's t-test for continuous variables or Chi-squared test for categorical variables. P value of less than 0.05 were considered statistically significant. RESULTS: Only 5% of respondents (11 of 210) used an inexpensive generic program to fill at least one of their prescriptions. Characteristics of patients who tended to use the generic programs included greater number of prescriptions, lower household income, no prescription insurance, and be of female gender. The study is limited in generalizability due to the small number of respondents in the group who had a prescription filled by an inexpensive generic program. CONCLUSIONS: This small study provides encouraging data to support the development of a larger study of the influence of the generic programs on patient behavior in regards to decision of where to obtain prescriptions. Larger studies may also attempt to determine whether these programs improve access to medications that patients may have had trouble affording before their inception.
PHP22 UTILIZATION OF PRESCRIBED PAIN MEDICATIONS PRIOR TO THE INITIATION OF DULOXETINE THERAPY
Zhao Y 1 , Wu N 2 , Chen SY 2 , Nagar S 2 , Boulanger L 2 1 Eli Lilly and Company, Indianapolis, IN, USA, 2 Abt Bio-Pharma Solutions, Inc., Lexington, MA, USA OBJECTIVES: Duloxetine is approved for the treatment of major depressive disorder (MDD) and general anxiety disorder (GAD), and for the management of diabetic peripheral neuropathic pain (DPNP) and fibromyalgia. It has also demonstrated significant pain relief among patients with chronic lower back pain (CLBP) and osteoarthritis. For patients with each of these conditions, this study assessed pain medication use prior to duloxetine initiation. METHODS: A large, US administrative claims database was used to identify commercially-insured duloxetine initiators during 2007 and 2008 who had any of the 6 medical conditions mentioned above during the 12 months prior to duloxetine initiation. Initiation was defined as no duloxetine pill coverage in the previous 90 days. Utilization of pain-related medications including antidepressants, anticonvulsants, opioids, non-steroidal anti-inflammatory drugs (NSAIDs), and muscle relaxants, was assessed over the 6 or 12 months prior to duloxetine initiation, respectively. RESULTS: The study identified 44,838 duloxetine initiators in 2008, with 13,809, 3,289, 1,501, 8,731, 7,871, and 18,987 Over 700 new molecular entities (NMEs) were approved between 1980 and 2008 in the U.S. Although a small percentage of these products will inevitably be discontinued, concerns over safety are purported to be the main impetus for discontinuing a drug from the market. In this study, a trend analysis was performed to examine the pattern of discontinued NMEs approved by the FDA from 1980 to 2008. METHODS: Data were derived from the FDA, Federal Register, Micromedex, Medline, Lexis-Nexis, journal articles, governmental web pages and other publicly available documents. A drug was considered discontinued if it was deleted from the 2009 version of the FDA's Orange book: Approved Drug Products with Therapeutic Equivalence Evaluations. Descriptive statistics, chi-square tests, logistic regression, and survival analysis were performed. For the Kaplan-Meier survival curves, drug that were not discontinued during the study time-period were censored. RESULTS: A total of 703 NMEs were approved during the study period. Of the 101 NMEs that were discontinued, 29 were due to safety concerns. Controlling for other factors, the odds (OR:2.53; 95% CI:1.42-4.55) of a drug being discontinued for reasons other than safety and efficacy were significantly higher than the odds of being discontinued for safety reasons (p < 0.05). Compared to other therapeutic classes, anti-infective drugs were more likely to be discontinued (p < 0.05). Results from the Kaplan-Meier survival analysis revealed the estimated probability of discontinuing a NME from the market over a 20 year time period was 15.0%. CONCLUSIONS: Survival analysis provided useful estimates for the probability of discontinuation. Safety concerns for NMEs were not the foremost reasons for drug discontinuation; rather financial reasons may contribute to a larger portion of discontinuations. However, additional studies are needed to assess how probabilities for drug discontinuation are influenced by decision-making entities regarding drug approval, drug development and innovation, and drug policy.
PHP24 THE PRESCRIPTION DRUG BURDEN FOR US ADULTS BETWEEN THE AGES OF 55 TO 64
Sepulveda B 1 , Baumgartner J 1 , Wiederkehr DP 1 , Doyle J 2 1 Quintiles Consulting, Hawthorne, NY, USA, 2 Quintiles Global Consulting, Hawthorne, NY, USA OBJECTIVES: With US health care reform proposing to extend Medicare coverage to individuals between the ages of 55-64, the pressure for coverage will dramatically increase. We examined demand five drug markets-cholesterol, diabetes, depression, hypertension and pain-for this age group compared to others. We also compared the cost burden under Medicare Part D compared payers to highlight the demand for more affordable drugs from individuals that are not yet eligible for Medicare coverage. METHODS: For each drug market, total prescriptions (TRx), new patient prescriptions (NPRx), and average prescription size were obtained for each of the age groups analyzed (≤18, 19-35, 36-54, 55-64, ≥65) . For each drug market, average out of pocket cost (OPC) was also compared between Medicare beneficiaries and other patients. Data were collected for eight quarters, spanning November 2007 to Novem-ber 2009 using SDI's VONA and VOPA databases. Statistical analyses were performed using one-way ANOVA; significant results had p < 0.05. RESULTS: Although individuals ages 55-64 did not dominate the NPRx-ranging from 15% to 26%-this group was the second-largest contributor to all prescriptions (TRx) for all the drug markets, ranging from 20% to 30%. The average size of prescriptions for this age range was statistically equivalent to the average size for the ≥65 population, indicating that prescriptions were refilled equally frequently in both populations. Medicare beneficiaries paid significantly less, on average, for drugs in the five classes compared to others by a margin of 20% to 93%. CONCLUSIONS: Individuals approaching Medicare eligibility are a demographic with significant demand for coverage. They show consistently high drug demand; prescription sizes are equal to patients over 65 and costs significantly higher Medicare patients, resulting in a great expenditure for covering this population. From the consumer perspective, it is important to recognize that the combination of higher OPC and high prescription demand creates a significant cost burden. 
PHP25 ASSESSING TRENDS IN UTILIZATION AND COST OF THE SIX PROTECTED MEDICATION CLASSES IN THE PART D PROGRAM

PHP26 THE IMPACT OF MISUSE OF ANTIBIOTIC THERAPIES ON INPATIENT COSTS
Yang L Peking university, Beijing, Beijing, China OBJECTIVES: In the 1980s, China launched market-oriented reforms. Public hospitals were encouraged to make their own incomes with the aim of mobilizing medical workers and improving hospital efficiency. Less government funding resulted in deficits for public health institutions, which forced hospitals to generate their own revenue by aggressively selling drugs, especially antibiotics. To stem the tide of rising public complaints about high medical costs, the NDRC has capped the cost of hundreds of drugs over the years. However, critics argue the price cuts have not been the cure since drug manufacturers often change the name and packaging of their drugs to escape price controls. Some hospitals and clinics have also turned a blind eye to government price caps and refuse to prescribe lower priced alternative drugs. This study was designed to evaluate the impact of inappropriate antibiotic use on inpatients' cost during the hospital stay. METHODS: One thousand cases with antibiotic treatment from 10 hospitals of 5 provinces in China in 2005. We created multivariate linear regression model for hospital cost and logistic regression model for rationality evaluation of antibiotic use. RESULTS: We collected 964 valid cases. Rate of inappropriate antibiotic use was 58.4%. Costs of inpatients with inappropriate antibiotic use was as 2.75 times as the ones with appropriate use (P < 0.001). Risk factors included antibiotic prophylaxis (OR = 2.929), operations (OR = 2.44), long hospital stay (OR = 1.021 for every prolonged day) and regional factors. Protection factor was in tertiary hospital (OR = 0.510). CONCLUSIONS: Inappropriate antibiotic use contributes to inpatients' high cost. Efforts to control misuse of antibiotic should be pursued.
PHP27 TRENDS IN EMERGENCY DEPARTMENT VISITS DUE TO OPIOID ABUSE IN THE UNITED STATES, 1996-2007
Bhurke S, Li C University of Arkansas for Medical Sciences, Little Rock, AR, USA OBJECTIVES: To study the trends in emergency department (ED) visits due to opioid abuse from 1996 to 2007 in United States. METHODS: ED visits attributable to opioid abuse were identified using diagnosis codes (ICD-9-CM codes: 304.0, 304.7, 305.5 and 965.0) from the National Hospital Ambulatory Medical Care Survey. Annual rate of ED visits for opioid abuse per 1000 people was estimated. To increase estimation precision, data from two consecutive years were pooled. Bivariate analysis and logistic regression were performed to examine the associations of patient demographic characteristics to ED visits for opioid abuse. Data were analyzed using STATA 9.2 accounting for complex survey design. RESULTS: Of the total 1,289,529,680 estimated ED visits made during the 12-year period, 1,633,224 (0.13%) were attributable to opioid abuse. ED visits for opioid abuse increased from 70,748 visits per year (0.08%) in 1996-1997 to 208,378 (0.18%) .6 days length of stay, and $14,808 ± 24,868 in charges. Further, 1.3% of cases resulted in patient mortality, which averaged 55.3 ± 19.5 years of age, 5.7 ± 9.1 days length of stay, and $44,904 ± 64,738 in charges. The national bill associated with OTC poisonings totaled $5.25 billion across the 5 years. Increased odds of inpatient mortality were associated (p ≤ 0.05) with patient age, total charges, number of comorbidities, patients who self-pay, the regional location of hospitals in the United States, and increased case-mix severities. Conversely, decreased odds of inpatient mortality were associated (p ≤ 0.05) with shorter lengths of stay, bed-sizes of hospitals, hospitals in urban settings, and teaching hospitals. CONCLUSIONS: Inpatient hospitalizations associated with poisonings from OTC medications accounts for a substantial burden of illness often exceeding 50,000 cases per year and summing to $5.25 billion over five years. Despite a small percentage of inpatient mortality, further research is needed on the costs and outcomes following discharge, as well as those treated and released solely in emergency departments, and OTC poisonings among children.
PHP28 EPISODES OF CARE AND INPATIENT MORTALITY FOLLOWING POISONINGS FROM OVER-THE-COUNTER MEDICATIONS IN THE UNITED STATES
PHP29 SPATIAL DEPENDENCE (OR CLUSTER) IN TOTAL NUMBER OF PRESCRIPTION DRUGS FILLED AT RETAIL PHARMACIES IN US
Kim J, Nickman N University of Utah, Salt Lake City, UT, USA OBJECTIVES: To examines the presence of spatial clusters across states in total number of prescription drugs filled at retail pharmacies in US METHODS: Using data on total number of prescription drugs filled at retail pharmacies by each state in US from Vector One and National by Verispan, L.L.C in 2008, Moran's I statistic for global spatial dependence (i.e. cluster) was used to identify if clusters existed. In Moran's I, weight matrix to define neighbors was utilized using Rook 1 st order contiguity weight, Queen 1 st order contiguity and 4-nearest neighbors. Permutations using 999 repetitions was used to calculate p-values in each weight matrix. RESULTS: Significant positive global spatial autocorrelation in total number of prescription drugs filled at retail pharmacies was found regardless of any weight matrix. Moran's I using Rook weight was 0.259 and p-value was 0.003. Moran's I using Queen weight and 4-nearest neighbors were 0.263 (p-value = 0.002) and 0.412 (p-value = 0.001), respectively. CONCLUSIONS: Findings showed that clusters or non-randomness in total number of prescription drugs filled at retail pharmacies existed. Non-randomness implies two things. In statistical analysis, this cluster effect should be considered. And, policy makers should consider clusters when they make a decision for health care distributions.
